ArticleFrontiers in oncology2025
Case Report: Tumor lysis syndrome in advanced, massive hepatocellular carcinoma with main portal vein invasion following atezolizumab plus bevacizumab therapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor lysis syndrome (TLS) is extraordinarily rare in solid tumors. However, the combination of atezolizumab and bevacizumab (AB) in advanced hepatocellular carcinoma (HCC) has raised concerns for abrupt metabolic derangements. We describe a fatal episode of TLS precipitated by AB in HCC with main portal vein (Vp4) invasion, highlighting the need for vigilant risk stratification and early biochemical surveillance for high-tumor-burden disease. Case presentation: A 65-year-old man with chronic hepatitis B and massive HCC (Vp4 invasion) had relatively preserved organ function at baseline. Two days after initiating atezolizumab (1,200 mg) and bevacizumab (15 mg/kg), he developed fever (38.5°C) and tachycardia (heart rate 112 beats/min [bpm]), rapidly progressing to circulatory shock on day 3. Laboratory workup revealed hyperuricemia (12.4 mg/dL), hyperphosphatemia (12.9 mg/dL), hyperkalemia (6.8 mmol/L), hypocalcemia (7.7 mg/dL), and acute kidney injury, meeting the Cairo-Bishop criteria for TLS. Imaging demonstrated abrupt cystic changes of the hepatic mass, suggesting rapid tumor necrosis. Despite aggressive fluid resuscitation and the initiation of hemodialysis, the patient succumbed to multiorgan failure within eight days after initiating AB. Conclusion: This case underscores that advanced HCC with extensive vascular invasion is at risk of severe TLS shortly after potent immuno-antiangiogenic therapy. Clinicians should incorporate thorough baseline risk assessments, prompt laboratory monitoring, and timely intervention into standard care algorithms for high-risk HCC. The rapid metabolic collapse observed here serves as a reminder that while combination therapy holds promise for improving survival in advanced HCC, it can also lead to life-threatening complications in specific subgroups. Careful selection of therapeutic options and shared decision-making with patients are critical to balancing potential benefits against severe adverse events, such as TLS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.